Mesoblast (ASX:MSB) said JPMorgan Chase & Co and its affiliates reduced their voting power in the company to 7.16% from 8.34% on Tuesday, according to a Friday filing with the Australian bourse.
The financial services firm and its affiliates reduced its shareholdings in the biotechnology firm to 82,2 million shares from 95.3 million shares as of the last notice dated Dec. 19, the filing said.